Expression Patterns of Matricellular Proteins in Metastatic Breast Cancer at the Background of Metabolic Syndrome

Authors

  • A.D. NEBORETS R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • S.I. NIKOLAYENKO Department of Pathological Anatomy, O.O. Bogomolets National Medical University, Kyiv, Ukraine
  • I.I. SMOLANKA State Non-Profit Enterprise "National Cancer Institute", Kyiv, Ukraine
  • M.S. KROTEVYCH State Non-Profit Enterprise "National Cancer Institute", Kyiv, Ukraine
  • V.V. MED State Non-Profit Enterprise "National Cancer Institute", Kyiv, Ukraine
  • S.G. GICHKA Department of Pathological Anatomy, O.O. Bogomolets National Medical University, Kyiv, Ukraine
  • V.F. CHEKHUN R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.04.333

Keywords:

metastatic breast cancer, matricellular proteins, osteopontin, osteonectin, metabolic syndrome

Abstract

Background. Metastatic breast cancer (mBCa) is one of the main causes of mortality among postmenopausal women with malignant neoplasms. Numerous studies indicate the feasibility of using bone matrix remodeling proteins to predict the BC course. Aim. To investigate the relationship between osteopontin (OPN) and osteonectin (ON) expression levels in tumor tissue of patients of menopausal age with primary mBCa (pmBCa) and metabolic syndrome (MetS) taking into account the clinicopathological features of the disease. Materials and Methods. The study included 54 menopausal patients with pmBCa, 23 from whom had manifestations of MetS, while 31 patients were without MetS. The expression of matricellular proteins (OPN and ON) was determined immunohistochemically. Results. In tumor tissue of patients with MetS and pmBCa of category N3, an increase in the level of OPN expression (H-Score of 265.6 ± 7.7, p < 0.05) was recorded along with a decrease in the expression level of ON (H-Score of 123.2 ± 7.7, p < 0.05). The invasive lobular pmBCa in patients with MetS was characterized by a significant decrease in the level of OPN expression ( H-Score of 219.4 ± 8.4) and an increase in ON expression (H-Score of 144.8 ± 7.5). In the patients with MetS, a significant decrease in ON expression (p < 0.05) was recorded in the tumor tissue of luminal A, luminal B, and Her2/neu subtypes ( H-Scores of 140.2 ± 7.8, 119.3 ± 10.2, and 110.0 ± 7.7, respectively). Among the cases of pmBCa with diagnosed metastatic liver disease, ON expression in tumor tissue was lower in patients with MetS (H-Score of 146.2±9.1). Conclusions. The obtained data demonstrated the relationship between the expression indicators of matricellular proteins in the pmBCa tissue and the degree of malignancy and indicated the prospects for further studies of their prognostic value in the presence of MetS.

References

Fedorenko ZP, Sumkina OV, Gulak LO, et al. Cancer in Ukraine 2022-2023: Incidence, mortality, prevalence, and other relevant statistics. Bull Nat Cancer Reg Ukraine. 2024:25. Available from: http://ncru.inf.ua/publications/ BULL_25/index_e.htm.

Im SA, Gennari A, Park YH, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open. 2023;8(3):101541. https://doi.org/10.1016/j. esmoop.2023.101541

Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treat- ment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-1495. https://doi.org/10.1016/j.an- nonc.2021.09.019

Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer. 2008;112(11 Suppl):2577-2592. https://doi.org/10.1002/cncr.23448

Clarijs ME, Thurell J, Kühn F, et al. Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: the need for a standardized approach. Cancers. 2021;13(10):2308. https://doi.org/10.3390/ cancers13102308

Tyczynski, JE, Plesko I, Aareleid T, et al. Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. Int J Cancer. 2004;112(6):1056-1064. https://doi.org/10.1002/ijc.20514

Qureshi R, Picon-Ruiz M, Sho M, et al. Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis. Cell Rep. 2022;41(7):111672. https://doi. org/10.1016/j.celrep.2022.111672

Dong S, Wang Z, Shen K, et al. Metabolic syndrome and breast cancer: prevalence, treatment response, and progno- sis. Front Oncol. 2021;11:629-666. https://doi.org/10.3389/fonc.2021.629666

Sankofi BM, Valencia-Rincón E, Sekhri M, et al. The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism. Front Endocrinol. 2023;14. https://doi.org/10.3389/fendo.2023.1217875

Wang X, Hui TL, Wang MQ, et al. Body mass index at diagnosis as a prognostic factor for early-stage invasive breast cancer after surgical resection. Oncol Res Treat. 2019;42:195-201. https://doi.org/10.1159/000496548

Gribach SM, Borodai NV, Chekhun VF. Clinical and biological features in elderly patients with breast cancer. Onco- logy. 2011;13(4):260-265 (In Ukrainian).

Heer E, Harper A, Escandor N, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8:e1027-e1037. https://doi.org/10.1016/S2214-109X(20)30215-1

Agnoli C, Berrino F, Abagnato CA, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis. 2010;20:41-48. https://doi.org/10.1016/j.num- ecd.2009.02.006

Bernstein LM. Diabetes, obesity and oncological morbidity: risks and anti-risks. Diab Mel. 2012;4:S81-S88. https:// doi.org/10.37469/0507-3758-2013-59-3-292-298

Recinella L, Orlando G, Ferrante C, et al. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front Physiol. 2020;11:578966. https://doi.org/10.3389/fphys.2020.578966.

Chekhun V, Pavlova A, Zadvornyi T, et al. Expression of SPP1 and SPARC genes in tumor tissue of patients with breast cancer. Exp Oncol. 2024;46(1):13-21. https://doi.org/10.15407/exp¬oncology.2024.01.013

Chekhun V, Borikun T, Zadvornyi T, et al. Osteonectin (SPARC) prognostic value in prostate cancer. Pathol Res Pract. 2024;254:155053. https://doi.org/10.1016/j.prp.2023.155053

Zadvornyi T, Lukianova N, Borikun T, et al. Еxpression of osteopontin and osteonectin in breast and prostate cancer cells with different sensitivity to doxorubicin. Exp Oncol. 2022;44(2):107-112. https://doi.org/10.32471/exponcol- ogy.23128852.vol44no2.17886

Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem. 1999;47(12):1495-1505. https://doi.org/10.1177/002215549904701201

Chen J, Zeng P, Gong L, et al. Osteopontin exacerbates high-fat diet-induced metabolic disorders in a microbiome- dependent manner. mBio. 2022;13(6):e0253122. https://doi.org/10.1128/mbio.02531-22

Ahmad R, Al-Mass A, Al-Ghawas D, et al. Interaction of osteopontin with IL-18 in obese individuals: implications for insulin resistance. PLoS One. 2013;8(5):e63944. https://doi.org/10.1371/journal.pone.0063944

Kos K, Wilding JP. SPARC: a key player in pathologies associated with obesity and diabetes. Nat Rev Endocrinol. 2010;6(4):225-235. https://doi.org/10.1038/nrendo.2010.18

Lukianova N, Zadvornyi T, Kashuba E, et al. Expression of markers of bone tissue remodeling in breast cancer and prostate cancer cells in vitro. Exp Oncol. 2023;44(1):39-46. https://doi.org/10.32471/exp-oncology.2312-8852. vol-44-no-1.17354

Sarikoc F, Kalinli A, Akgun H, Öztürk F. An automated prognosis system for estrogen hormone status assessment in breast cancer tissue samples. Turk J Electr Engin Comp Sci. 2013;21:1199-1121. https://doi.org/10.3906/elk-1111-10

Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997-4013. https://doi.org/10.1200/JCO.2013.50.9984

Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Patholo- gists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. https://doi.org/10.5858/2007-131-18-ASOCCO

Jason RB, Michael PD, Killelea B, et al. Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. Lab Invest. 2014;94(1):98-106. https://doi.org/10.1038/labinvest.2013.128

McClelland RA, Wilson D, Leake R, et al. A multicenter study into the reliability of steroid receptor immunocytochemi- cal assay quantifi ation. Eur J Cancer Clin Oncol. 1991;27:711-715. https://doi.org/10.1016/0277-5379(91)90171-9.31

Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue — a review. Diagn Pathol. 2014;9:221. https://doi.org/10.1186/s13000-014-0221-9

Ghanemi A, Yoshioka M, St-Amand J. Secreted protein acidic and rich in cysteine (SPARC)-mediated exercise ef- fects: illustrative molecular pathways against various diseases. Diseases. 2023;11(1):33. https://doi.org/10.3390/dis- eases11010033

Barker TH, Baneyx G, Cardó-Vila M, et al. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem. 2005;280(43):36483-36493. https://doi.org/10.1074/jbc.M504663200

Wohlgemuth RP, Brashear SE, Smith LR. Alignment, cross linking, and beyond: a collagen architect's guide to the skeletal muscle extracellular matrix. Am J Physiol Cell Physiol. 2023;325(4):1017-1030. https://doi.org/10.1152/ajp- cell.00287.2023

Kamml J, Ke CY, Acevedo C, et al. The influence of AGEs and enzymatic cross-links on the mechanical properties of collagen fibrils. J Mech Behav Biomed Mater. 2023;143:105870. https://doi.org/10.1016/j.jmbbm.2023.105870

Anborgh PH, Mutrie JC, Tuck AB, et al. Role of the metastasis-promoting protein osteopontin in the tumor micro- environment. J Cell Mol Med. 2010;14(8):2037-2044. https://doi.org/10.1111/j.1582-4934.2010.01115.x

Kamalabadi-Farahani M, Atashi A, Jabbarpour Z, et al. Expression of osteopontin-5 splice variant in the mouse primary and metastatic breast cancer cells. BMC Res Notes. 2022;15(1):286. https://doi.org/10.1186/s13104-022- 06179-w

He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006;25:2192-2202. https://doi.org/10.1038/sj.onc.1209248

Fnu G, Weber GF. Osteopontin induces mitochondrial biogenesis in deadherent cancer cells. Oncotarget. 2023;14:957- 969. https://doi.org/10.18632/oncotarget.28540

Bhaludin BN, Tunariu N, Koh D-M, et al. A review on the added value of whole-body MRI in metastatic lobular breast cancer. Eur Radiol. 2022;32:6514-6525. https://doi.org/10.1007/s00330-022-08714-6

Chen Z, Yang J, Li S, et al. Invasive lobular carcinoma of the breast: A special histological type compared with inva- sive ductal carcinoma. PLoS One. 2017;12(9):e0182397. https://doi.org/10.1371/journal.pone.0182397

Neborets AD, Naleskina LA. Cytoarchitectonics of tumors different by molecular subtype in BC`s patients with meta- bolic syndrome. Oncology. 2024;26(3). https://doi.org/https://doi.org/10.15407/oncology.2024.03.172 (in Ukrainian).

Abdallah H, Elwy A, Alsayed A, et al. Metastatic breast lobular carcinoma to unusual sites: a report of three cases and review of literature. J Med Cases. 2020;11(9):292-295. https://doi.org/10.14740/jmc3538

Batra H, Mouabbi JA, Ding Q, et al. Lobular carcinoma of the breast: a comprehensive review with translational insights. Cancers. 2023;15(22):5491. https://doi.org/10.3390/cancers15225491

Arrangoiz R, Papavasiliou P, Dushkin H, Farma JM. Case report and literature review: Metastatic lobular carci- noma of the breast an unusual presentation. Int J Surg Case Rep. 2011;2(8):301-305. https://doi.org/10.1016/j. ijscr.2011.06.010

Harris M, Howell A, Chrissohou M, et al. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984;50(1):23-30. https://doi.org/10.1038/bjc.1984.135

Downloads

Published

20.02.2025

How to Cite

NEBORETS, A., NIKOLAYENKO, S., SMOLANKA, I., KROTEVYCH, M., MED, V., GICHKA, S., & CHEKHUN, V. (2025). Expression Patterns of Matricellular Proteins in Metastatic Breast Cancer at the Background of Metabolic Syndrome. Experimental Oncology, 46(4), 333–340. https://doi.org/10.15407/exp-oncology.2024.04.333

Issue

Section

Original contributions

Most read articles by the same author(s)

1 2 > >>